VTVT: vTv Therapeutics Inc. Class A Common Stock Company Profile & Statistics

About

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.

Info & Links

CEO

Paul J. Sekhri

Headquarters

3980 PREMIER DR, SUITE 310
HIGH POINT, NC 27265, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

vTv Therapeutics Inc. Class A Common Stock Statistics

Valuation Measures

Market Capitalization²

62.66M

Enterprise Value

21.09M

Enterprise Value/EBITDA(ttm)

-0.88

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

3.72

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-121.63%

Return on Equity(ttm)

-184.64%

Return on Invested Capital(ttm)

-69.13%

Return on Assets(ttm)

-47.29%

Income Statement

Revenue(ttm)

1000.00K

Revenue Per Share(ttm)

0.31

Gross Profit(ttm)

1000.00K

EBITDA(ttm)³

-23.91M

Net Income Available to Common(ttm)

-18.31M

Diluted EPS(ttm)

-4.53

Share Statistics

Beta (5Y Monthly)

0.73

52-Week Change

132.78%

S&P 500 52-Week Change

18.02%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

3.19M

Dividend Yield

0.00%

Float⁴

3.15M

% Held by Insiders

1.34%

% Held by Institutions

17.51%

Balance Sheet

Total Cash(mrq)

41.57M

Total Cash Per Share(mrq)

13.03

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.69%

Quick Ratio(mrq)

6.69%

Book Value Per Share(mrq)

5.62

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.75

Free Cash Flow(ytd)

-20.48M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

VTVT

vTv Therapeutics Inc. Class A Common Stock

vTv Therapeutics Inc. Class A Common Stock Profile